Skip to main
IFRX

InflaRx (IFRX) Stock Forecast & Price Target

InflaRx (IFRX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

InflaRx is a promising company with a positive outlook due to its innovative and effective product candidates, especially Izicopan and vilobelimab, for the treatment of autoimmune and inflammatory diseases. The company's potential for high sales, improved safety and convenience, and potential partnerships make it a strong contender in the biopharmaceutical market. The setbacks faced by its competitor, Tavneos, also give InflaRx a potential advantage. The company's ongoing discussions with regulatory agencies and positive updates suggest a positive potential for success, making it a compelling investment opportunity.

Bears say

InflaRx is facing significant challenges with its flagship product, Tavneos, due to safety concerns and allegations of data integrity issues. Moreover, the company's lack of visibility on ROW sales adds to the uncertainty around its financial performance. Despite having a potentially promising pipeline and a unique mechanism of action, InflaRx faces numerous risks and hurdles in successfully developing and commercializing its products.

InflaRx (IFRX) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InflaRx (IFRX) Forecast

Analysts have given InflaRx (IFRX) a Buy based on their latest research and market trends.

According to 6 analysts, InflaRx (IFRX) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InflaRx (IFRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.